Transcript 0:00 [on-hold music] Hey, everyone. Thanks so much for joining me. I'm your host, Jared Taylor. 0:14 Joining me today is the CEO and the Chief Scientific Officer of Ratio Therapeutics. Really excited to have you gentlemen on the podcast today. How are you? Great. Happy to be here. Nice to be here, Jared. 0:26 Well, I, I'd love to start by, uh, giving you each an opportunity to, you know, talk about yourself. Like, give us the snapshot of each of you, and then let's dive more into Ratio Therapeutics. 0:37 But whatever order you, you gentlemen would like to go into, uh, tell us a little bit about yourself. Great. I'll, I'll kick off and then I'll pass it to John to kind of give the, uh, how we got here. Yeah. 0:49 His background and how we got here. So Jack Hoppin. I'm a mathematician by training, uh, with a background in molecular imaging. 0:57 Um, have worked in the nuclear imaging and nuclear medicine space basically my whole career, um, post grad school, post-doc and on. Uh, relevant to this conversation, started in the, in the 1:12 imaging hardware business, making an imaging system. I was at a German lab, moved to Hungary where we made that into a product. 1:18 Um, a few years in, thought it would be a good idea to, to really focus on the software and services a-aspect of that technology, uh, and started a company in Boston in 2008 by the name of Invicro. 1:32 Um, grew that company over the course of a decade or so and, uh, to a few hundred people doing a lot of i-imaging research in, in pharmaceutical trials, both discovery all the way through to late-stage trials. 1:45 And, uh, very technical company, and sold that company to Konica Minolta Precision Medicine in 2017. 1:52 Uh, stayed on at Konica Minolta, first continuing to run Invicro and then, uh, as the president of their precision medicine business which had imaging, genomics and digital pathology. 2:04 Um, that's along the way I met, uh, I met John Babich a couple times, but we, we reconnected in 2018. Uh, in 2020, I, um, decided to 2:17 retire, which I failed at, as you're about to hear, and, uh, and I'll, I'll pass it to John now. I, I would say he failed up. [laughs] Yeah, that's it. Yeah, exactly. Yeah, so John Babich. 2:27 My background is in, uh, pharmaceutical chemistry. Um, my whole career has been devoted to nuclear medicine. Started out at Brookhaven National Laboratories. 2:36 Uh, did some work at NASA and, uh, the Johnson Space Center looking at, you know, applications of imaging and, and how it affects, uh... and, and how zero-G affects, uh, physiology. 2:48 Uh, moved to the UK where I did my PhD at the Institute of Cancer Research. Went from there to MGH and, uh, really was focused on the study of, of drugs and their distribution. 2:59 Uh, worked with several big pharma companies on trying to understand how their drugs were working, uh, both, you know, throughout the body, but particularly in the brain. 3:08 Uh, got an interesting itch, uh, to start a company back in 1998, uh, a company called Molecular Insights Pharmaceuticals. Uh, took that out and, uh, developed that company in Cambridge, Mass. 3:22 Uh, built that to about 120 people at a peak. Uh, took that public in 2007. 3:27 Had a, a series of, uh, really, uh, cutting-edge clinical programs, including prostate cancer and neuroendocrine cancer, things that are top of the, top of the mindset of, uh, the, the topic that we'll talk about today. 3:40 And sold that company to Progenics in 2013. Uh, took a, a diversion back into academia and was thinking about really, um, how do we, how do we really think about, uh, targeted radiotherapeutics in general? 3:53 And I think we'll get into that in a second. But the idea of, of actually being able to inject a radioactive drug to, to find and treat metastases of cancer every-anywhere in the body. 4:05 And, uh, as we play with that idea and, and fine-tune that idea, um, we came up with a very interesting, um, scaffold, a very interesting platform where we can tune the, uh, pharmacokinetics in the body. 4:20 And that led to some very interesting thinking in that, which is, you know, can we optimize the PK? Is there a way to... 4:27 Is there, like, a golden rule about what's the, what's required for optimal localization of cancers? And at that time, I, I reached out to Jack. I knew Jack by his background and him and his, uh, his work in the field. 4:42 I said, "Jack, I have an interesting problem I think that, you know, your mathematical expertise would be-- would-- I'd love you to think about this problem with me." 4:50 And that was how do we optimize the delivery of drugs, radioactive drugs, to, uh, to tumors? And, uh, we got reacquainted back in, what, 2018. And, uh, we, we were working on a program in prostate cancer at the time. 5:05 We had spun a company out of my lab at Cornell called Noria Therapeutics that eventually got acquired by Bayer Pharmaceuticals. Uh, during that time, Jack was on the board. 5:15 We really worked hard to get that deal done together. And then, um, at the, at the actual execution of that deal or a week before, it became apparent to us that, uh, we needed to start another company. 5:29 So we started a company essentially with the same technology. We sold a particular use to, to Bayer in prostate cancer, but we recapitulated all those licenses and started Ratio Therapeutics. 5:41 We wound up with a very good relationship with Bayer out of that, and also another company called Antheus, uh, Pharmaceuticals here in Massachusetts. 5:48 And, uh, bootstrapped through those, those relationships on our own internal, uh, investments and created Ratio Therapeutics back in June of 2021. And, uh, here we are today. We've got our own, you know, our first IND. 6:02 We've got clinical programs going on, a lot of exciting things happening, and we're opening a headquarters in probably the end of February Here in the Seaport area of Boston. So it's kinda, kinda a short story. 6:15 In an absolutely beautiful area too. You have to throw that in there because this is-- I know the building you're talking about, and, uh, that area with the marina and everything. 6:27 I mean, y-you guys have a, a s-stressful day today, right? Being able to go outside real quick on a call or something and see that marina, that sun, when it's not winter, right? 6:36 [chuckles] Uh, it'll be, it'll be great, uh, for the, for the team. Um, thanks, thanks so much, John. Jack, I wanna touch on something that John mentioned, right? 6:48 Uh, he, he mentioned, you know, you being a mathematician, which is super interesting. I wanna dive more into, um, the-- like what, what you bring to Ratio as a mathematician. 6:58 Obviously, it's-- You're, you're more than just a, a mathematician, but I wanna h- focus in on that piece because, um, I, I don't hear that as, as much and, um, I really wanna focus in on it. Sure. 7:09 So, um, John really alluded to it that, um, by definition, this class of therapeutics is very quantitative. Uh, we can image the drug, and then we treat with the drug. 7:22 And John is, um, a, a very multimodal scientist, uh, who knows, uh, uh... Really had thought of the problem holistically. And when he came with this notion of tunable pharmacokinetics, which is tunable 7:38 biodistribution strategy for the drugs, um, my background is really in studying and quantifying the biodistribution of drugs and there's a lot of math in it. Um, there's a lot of math in imaging itself. 7:51 And in this case, there's very quantitative measures of if you are going to be able to create a drug that's going to be effective. 7:57 And when John showed up at our door and we met, I really thought the way he looked at the problem, which is how do we optimize this delivery system? 8:05 How do we optimize the ratio of residents to the tumor, to the ratio-- to, to the off target? That's really what, um, that's really what this activity's about. 8:15 And so, uh, we as a group, we're, we're only 20, 22 people right now, but very technical group across a broad spectrum of, of disciplines, and math is one of the components, math, physics, chemistry, biology, that supports the pharmacology to understand the pharmacodynamics of the drug. 8:32 And we have a core nucleus here that's really strong. I cannot help but to bring up that when we think about the-- one of the advantages of this class of drugs, we're always gonna image those drugs. 8:44 We, we do nuclear tomography, usually two modalities, sometimes three. So we, we have emission tomography, SPECT and PET, where we inject radioactivity and image where it goes. 8:54 And then we have transmission tomography, where we're using an X-ray source and looking at the attenuation map that is our bodies, the bone, all the different organ attenuation maps. 9:04 That t-tomography is the writing of slices, so I think it's only appropriate that you have tomographers on Slice of Healthcare. Uh, shameless pitch for, for, for slicing. 9:13 We-- So that's, that stacked slice of images is really gives us the best biomarker readout for our drugs possible. 9:20 And then we go to an alternative where we're trying to irradiate the tumor by, by injecting, you know, um, radionuclides on a drug that we're trying to target the tumor at. 9:31 So it-- T-that's the team and, and so I think it's really... Math is just one pillar of what comes, uh, together here. Now, the, the company owns two R&D platforms, right? 9:42 And if I butcher the second one, please forgive me. But Trillium and, and Mac-Macropa, is that-- Did I say it right or? Perfect. We accept all pronunciations of that. That's totally good. Perfect. 9:52 Um, so that's really cool. Can you talk a little bit about, you know, how each of them work? Sure. The, the, the Trillium is the, the platform that I alluded to in, in terms of the, uh, trying to understand 10:07 how you can design a molecule and, and, and make it as-- I'll try to make it as, as simple as possible. So Trillium is a, a flower, and so it's a, a three-pointed, uh, three-petal flower and, uh, 10:20 you know, it sounds better than tri-functional scaffold. So, you know, y- we have this Trillium scaffold, and it's, it has three components to it, right? 10:27 It has, it has a component to it that allows the binding to a, a protein that's on the surface of a cancer. So that's a tumor targeting p-component. And then it has a component that takes the radionuclide with it, right? 10:40 So what we're doing is really using the radionuclide, as Jack alluded to. We can see that, we can image that, but we really wanna, we wanna swap out the, the isotope for a therapeutic benefit to the patient. 10:52 So it c- it carries a payload. And then the third piece to this is this PK modulation motif. And what we have is a series of compounds that bind albumin reversibly. So they'll, they'll bind, you know, lots of drugs. 11:06 Lot-- Many, many drugs bind albumin, right? It's part of the solubilization after you take a tablet, things wind up. It's things like ibuprofen and other things, warfarin. 11:14 They, they bind to proteins in your plasma, and that's how they get delivered to the body and how they get solubilized. 11:19 But you can actually use it as a sort of feature to the molecule where you can dial in how much binding you have, and then it changes the plasma curve. 11:28 So i-if you-- And if everything we do is injectable, so as soon as you inject the drug, it's gonna see albumin, and it's gonna, it's gonna re- it's gonna be circulating around the body as a function of how, how tightly it binds albumin. 11:41 So we want something to stay there for a long period of time, have multiple passes through the, the tumor bed, then we can put something that's fairly strong. And that, that gives us the ability to do that. 11:51 If we wanna do something, say, uh, for imaging where we don't really need multiple passes, we're a b- a quick flush, and then we want everything to escape the plasma, then we have a very weak albumin binder on there. 12:02 So we have this range of, of, uh, affinities or strengths that we can, we can dial in. And that's, that's the Trillium scaffold. 12:10 We have the ability to change the payload, change the albumin binding domain, and actually change the tumor targeting domain, and we've been successful Uh, with two clinically, um, scaffolds that way. 12:21 The, the second scaffold really is a, a unique way of binding an alpha emitter called actinium-225. So this is a, a, a very, uh, potent anti-cancer alpha emitter. But the chemistry is kind of, uh, bulky, right? 12:37 This is something found in the bottom of the periodic table. It's big, it's clunky. It's not something you have a lot of experience with collectively. 12:45 But it turns out that macrociclopenta[di]ene actually binds this thing like hand in a glove, right? It just, it just goes in there, it goes in there very quickly. 12:53 It will not come out, uh, in any reasonable, you know, under any reasonable circumstances, both in a vial or in a patient or an animal subject. 13:03 So we have a way of actually putting these very potent isotopes onto our molecules very, very quickly and, and robustly, and it makes manufacturing much simpler and allows us to use actinium in a, in a, in a variety of applications. 13:19 And not just for Trillium, but we can also, um, use it for other constructs, right? Antibody constructs, small molecules, peptides, whatever it is. 13:27 It, it, it allows us to basically attach one of those molecules onto any vector and allow us to label with actinium and create a therapeutic out of it. So it's, it's quite unique that way. And, and by the way, 13:41 guys, I would love to have you both back on at some point, like on a panel to talk about this with, you know, with some, some of your peers. Maybe, you know, you alluded to a good relationship that you have. 13:51 I think it was, was it Bayer? Was that what, uh- Correct. Maybe we could have someone from Bayer come on as well to, to really dive into more of what you're talking about. 13:59 This is your first time on Slice of Healthcare, so I appreciate you giving us a really good overview of everything that you're doing. 14:06 Um, I, I wanna quickly shift focus to, uh, you know, before the conversation we were talking about JPM a little bit. I did not go this year, um, but I know, uh, John, you did. 14:17 Can you tell us a little bit, like how, how was the buzz? How was it? Uh, did you stay dry? [laughs] Yeah. This is Jack. Yeah. I, I, uh- Oh, I'm sorry... I did go. No, no, no problem. I, uh, um, I went. 14:29 Uh, it was exciting to be back in person, I would say. Um, I, I've seen it better attended, um, as you might expect be- between the, the weather and the kinda the, the time, you know, just everything ch- going on. 14:43 But I-- It was, it was booming. I mean, it, it, there was a lot of energy, and I have to say, uh, it, it delivered. I, I thought it was a really good conference. There was a, um, uh... 14:55 Mine was actually a li- it was probably a little positive. There were a few less people there. You could actually sit down in a couple places, whereas usually you can't even find a seat anywhere. 15:01 But, uh, targeted radiotherapy was, was certainly, um, discussed well across the, the panels. We did not present. We were just in attendant-- I was just at, in attendance and, and there for meetings. 15:14 Um, but the, the consistent messaging that we'll repeat right now is this new emerging, it's not really a new idea, but this, this emerging class and the adoption of this class of targeted radiotherapy with Novartis, Bayer, uh, really leading the way and, and a, and a, a class of companies similar to ourselves trying to innovate in the space and, and make the next generation of this class of, of drug, um, covering all the reasons it's, it's such a constructive therapy. 15:43 Uh, very little side effect, uh, works well with targeted, with, with immunotherapeutics. Um, it's a very rational alternative to external beam radiation, which is used basically in half of patients. 15:56 Um, and so there was a lot of buzz, I would say from where I sat, there was a lot of buzz around, uh, targeted radiotherapy. There was a lot of buzz around gene therapy, uh, so not really a surprise. 16:07 These are, uh, hot top- hot topics. Hot topics. Yeah. Yeah. 16:11 What, what are some, some hot topics or some exciting, uh, things that you can share for Ratio Therapeutics as we head into, you know, 2023 and beyond, that, that you can share at this time? You wanna talk about it? 16:23 Yeah. So our, our, our big push right now is really to, uh, to, to, to, to, to explore the opportunity that there's a particular target that the, the field is very excited about. 16:32 It's a, it's a target that is found on many cancers, many epithelial cancers called fibroblast activated protein alpha. 16:40 It sits not on the cancer cell itself, although it, it, it does show up in some cancers, but in, in a, in a, in a number of cancers. It's in the, 16:50 it's in the sort of tissue that supports tumor growth, so it's the, it's the, it's the cancer-associated fibroblast, the part of your body that reacts to a wound. 17:00 Basically, the tumor shows up, you know, as a wound, and then your body sort of reacts to it, and then in that reaction is actually supporting and covering the... 17:09 You know, it's kinda like building a nest for the cancer cells. And this is a very interesting opportunity. 17:15 It's been shown to be very useful at finding cancers, um, from an imaging perspective, and there's an opportunity to a- at least, you know, um, 17:24 theoretically, that if you can go after that particular target with a therapeutic, you have the opportunity to actually diminish the stromal component or the, or the protective component of the, of the host in protecting the tumor, which actually might open up opportunity for immuno-oncology applications and also act as either an adjuvant or also as a, as supporting therapy. 17:45 As, as you know, most, most cancer therapy is multimodality, multidrug, so this would be a component to that. 17:51 And we have, uh, some very exciting, uh, pre- preliminary data in that space, and we, we think that, uh, 2023 will be a big push for us to move forward with the, with the FAP therapeutic, uh, at Ratio Therapeutics. 18:03 Well, uh, gentlemen, I want to thank you once again for, for coming on as guests. We should really get that, that panel put together because I think the audience will really enjoy it. 18:11 I know you guys would have a ton of fun talking with, uh, with your colleagues over at Bayer. 18:17 Um, but really appreciate you coming on here, telling your story, telling our audience your story, and then, um, really getting them excited about what's, what's on the horizon. 18:26 And, uh, I, I really appreciate you talking through the, uh, your two R&D programs as well, which I found really interesting. Love the names too. Um, it's, it's not just- [laughs] It's not just a brewery. Yeah, we know. 18:40 [laughs] [laughs] Exactly. It is funny, though, that we are right next to the Trillium Brewery. It's like right here. Yeah. So obviously there's a lot of Trillium mugs and hats and shirts around here, you know. Yeah. 18:49 It's-- Yeah, for the audience, when you see this, where their, where their new office is going to be too, it is literally across the street. Um- [laughs] Yeah. It's, it's a good spot. 18:59 It's, um, really good- I had nothing to do with it. Yeah. [laughs] Nothing to do with it. Yeah. Um, thank you, gentlemen, so much, um, and I wish you all the best of luck and an, an exciting 2023. Thanks so much. Thanks. 19:11 Appreciate it. [outro music]